AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28466557 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment in e13a2 patients
Number of subjects: 559
Study 28466686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative concomitant hyperfractionated radiotherapy (HART) with co-administration of 5-fluorouracil (5FU), total dose 42 Gy in 28 fractions of 1.5 Gy, two times daily.
Number of subjects: 51
Study 28467527 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 821
Study 28468687 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention 'Start to Stand'
Number of subjects: 155
Study 28468687 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention 'Start to Stand' with action planning
Number of subjects: 155
Study 28468797 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor, 3 to 80 mg/m²
Number of subjects: 79
Study 28468890 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 0
Study 28468890 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 28468891 — intervention group
Group type: EXPERIMENTAL
Intervention: lipid-rich ready-to-use therapeutic food
Number of subjects: 0
Study 28468891 — intervention group
Group type: EXPERIMENTAL
Intervention: phytase
Number of subjects: 0
Study 28468891 — intervention group
Group type: EXPERIMENTAL
Intervention: lipids
Number of subjects: 0
Study 28468891 — intervention group
Group type: COMPARATOR
Intervention: maize-based meals fortified with micronutrient powders
Number of subjects: 0
Study 28468895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 supplementation, dosage and duration not available
Number of subjects: 0
Study 28468895 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 28468947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral Injection
Number of subjects: 0
Study 28469486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate with single dose of Calcium Gluconate (SBCG1)
Number of subjects: 0
Study 28469486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate with double dose of Calcium Gluconate (SBCG2)
Number of subjects: 0
Study 28469486 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 0
Study 28469670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 0
Study 28469697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 1225
Study 28469697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 1225
Study 28470739 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 16
Study 28470739 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 16
Study 28470739 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 28470815 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR+GZR+RBV for 12 weeks
Number of subjects: 41
Study 28470815 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR+GZR+RBV for 18 weeks
Number of subjects: 41
Study 28470815 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment virologic failure
Number of subjects: 41
Study 28470815 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-associated substitutions (RASs) at virologic failure
Number of subjects: 41
Study 28470815 — intervention group
Group type: EXPERIMENTAL
Intervention: Common RAS at virologic failure
Number of subjects: 41
Study 28470856 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Research for Development
Number of subjects: 52
Study 28470994 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 142
Study 28470994 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 142
Study 28470994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 142
Study 28470994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding risk
Number of subjects: 142
Study 28470994 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 142
Study 28470994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 142
Study 28471286 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) adherence measured by a 4-item self-report questionnaire
Number of subjects: 319
Study 28471286 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) adherence measured by a single question (SQ)
Number of subjects: 319
Study 28471286 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) adherence measured by medication possession ratio (MPR)
Number of subjects: 319
Study 28471286 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with ICS adherence
Number of subjects: 319
Study 28471286 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of asthma severity and risk of death
Number of subjects: 319
Study 28471445 — intervention group
Group type: EXPERIMENTAL
Intervention: Type H vessel identification, positive for CD31 and Endomucin
Number of subjects: 0
Study 28471765 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antiretroviral therapy (ART)
Number of subjects: 3313
Study 28472039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18)
Number of subjects: 76
Study 28472039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18) for F2 prediction
Number of subjects: 76
Study 28472039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18) for advanced fibrosis (F3-4) prediction
Number of subjects: 76
Study 28472039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18) among patients without hyperuricemia
Number of subjects: 76
Study 28472067 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine
Number of subjects: 36
Study 28472325 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51
Study 28472325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 28472325 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide and Placebo
Number of subjects: 51
Study 28472325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercodia assay
Number of subjects: 51
Study 28472366 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide or abiraterone in chemotherapy-naïve patients
Number of subjects: 265
Study 28472366 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide or abiraterone in post-docetaxel patients
Number of subjects: 265
Study 28472366 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide in PREMIERE trial
Number of subjects: 265
Study 28472366 — intervention group
Group type: EXPERIMENTAL
Intervention: AR mutations in post-docetaxel patients
Number of subjects: 265
Study 28472437 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin 100 mg once daily
Number of subjects: 513
Study 28472437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 28472487 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-oxygenated steroids (11OHA4, 11OHT, 11ketoT, 11ketoA4)
Number of subjects: 114
Study 28472487 — intervention group
Group type: COMPARATOR
Intervention: 11OHA4, 11OHT, 11ketoT, 11ketoA4, PregS
Number of subjects: 114
Study 28472487 — intervention group
Group type: COMPARATOR
Intervention: PregS, 17-hydroxypregnenolone sulfate
Number of subjects: 114
Study 28472487 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels
Number of subjects: 114
Study 28472509 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) 200 mg/m2 × 5/28 day for 6 cycles followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT).
Number of subjects: 41
Study 28472509 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC (thiotepa 250 mg/m2/day × 3 days, then busulfan 3.2 mg/kg/day × 3 days) followed by ASCT.
Number of subjects: 41
Study 28472928 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions
Number of subjects: 512
Study 28472928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-adherence preparation
Number of subjects: 512
Study 28472928 — intervention group
Group type: EXPERIMENTAL
Intervention: Support groups
Number of subjects: 512
Study 28472928 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Number of subjects: 512
Study 28472928 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 512
Study 28472957 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR97276A (IM: 0.18 mg/kg; IV: 0.14 mg/kg)
Number of subjects: 113
Study 28472957 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR97276A (3-day IM regimen)
Number of subjects: 113
Study 28472957 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR97276A (0.5 mg/kg once daily for 3 days)
Number of subjects: 113
Study 28472957 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR97276A (0.25 mg/kg twice daily for 3 days)
Number of subjects: 113
Study 28472957 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (control group)
Number of subjects: 113
Study 28472974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber cardiac pacing 'on' with Closed Loop Stimulation
Number of subjects: 128
Study 28472974 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber cardiac pacing 'off' (placebo)
Number of subjects: 128
Study 28473128 — intervention group
Group type: EXPERIMENTAL
Intervention: Valve-in-valve TAVR
Number of subjects: 365
Study 28473206 — intervention group
Group type: EXPERIMENTAL
Intervention: SYD985
Number of subjects: 10
Study 28473206 — intervention group
Group type: COMPARATOR
Intervention: T-DM1
Number of subjects: 10
Study 28473406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study 28473600 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28473851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine Replacement Therapy
Number of subjects: 0
Study 28474366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanicemine (AZD6765) administered intravenously
Number of subjects: 191
Study 28474980 — intervention group
Group type: EXPERIMENTAL
Intervention: No DVT prophylaxis (medical or mechanical) during or after surgery
Number of subjects: 100
Study 28474985 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA+)
Number of subjects: 931
Study 28474985 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura (MA-)
Number of subjects: 931
Study 28474985 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (Control)
Number of subjects: 931
Study 28475354 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of glucose with insulin
Number of subjects: 0
Study 28475354 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition containing amino acids
Number of subjects: 0
Study 28475354 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of amino acids in critically ill mice
Number of subjects: 0
Study 28475354 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoneutralizing glucagon in critically ill mice
Number of subjects: 0
Study 28475690 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalus™ bioprosthesis
Number of subjects: 686
Study 28475704 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal-sparing geographic atrophy (GA)
Number of subjects: 65
Study 28475704 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal-sparing size >1.5 mm2
Number of subjects: 65
Study 28475704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge size <400 μm
Number of subjects: 65
Study 28475704 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic parameters
Number of subjects: 65
Study 28475704 — intervention group
Group type: EXPERIMENTAL
Intervention: Local regression curves
Number of subjects: 65
Study 28475735 — intervention group
Group type: EXPERIMENTAL
Intervention: Later-generation fluoroquinolone (moxifloxacin or levofloxacin)
Number of subjects: 834
Study 28475735 — intervention group
Group type: COMPARATOR
Intervention: Earlier-generation fluoroquinolone or no fluoroquinolone
Number of subjects: 834
Study 28476102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Recent Life Changes Questionnaire (RLCQ)
Number of subjects: 200
Study 28476102 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methodology and in-depth interviews
Number of subjects: 200
Study 28476102 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling exercise on the RLCQ
Number of subjects: 200
Study 28476102 — intervention group
Group type: EXPERIMENTAL
Intervention: Content and face validity exercises
Number of subjects: 200
Study 28476111 — intervention group
Group type: EXPERIMENTAL
Intervention: Single use bronchoscope (Ambu® aScope)
Number of subjects: 60
Study 28476111 — intervention group
Group type: COMPARATOR
Intervention: Conventional bronchoscope
Number of subjects: 60
Study 28476136 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise twice weekly for 12 weeks
Number of subjects: 300
Study 28476136 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 300
Study 28476148 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Self-management (SSM) intervention for 2 months, delivered by primary care and social workers.
Number of subjects: 0
Study 28476148 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control group) with a leaflet about depression.
Number of subjects: 0
Study 28476163 — intervention group
Group type: EXPERIMENTAL
Intervention: German version of the Tinnitus Functional Index (TFI)
Number of subjects: 264
Study 28476275 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine users (BZD)
Number of subjects: 476
Study 28476275 — intervention group
Group type: COMPARATOR
Intervention: Non-BZD users
Number of subjects: 476
Study 28476440 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 410
Study 28476440 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (375 mg/m2)
Number of subjects: 410
Study 28476440 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab
Number of subjects: 410
Study 28476440 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 410
Study 28476756 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled inorganic nitrite
Number of subjects: 0
Study 28476756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28476882 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual walking speed
Number of subjects: 926
Study 28476882 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light timing based on walking speed
Number of subjects: 926
Study 28476913 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant insertion
Number of subjects: 414
Study 28476913 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant insertion
Number of subjects: 414
Study 28476913 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA detected
Number of subjects: 414
Study 28476913 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase (1-year)
Number of subjects: 414
Study 28476931 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant rs11014566 (G allele)
Number of subjects: 5870
Study 28477061 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir in combination with peg-interferon and ribavirin (Peg-IFN/RBV)
Number of subjects: 46
Study 28477280 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples collected at arrival, 24, and 48 hours later for RNA gene expression analysis.
Number of subjects: 1000
Study 28477280 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study design.
Number of subjects: 1000
Study 28477280 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted evaluations and secondary prevention strategies initiated based on identified markers.
Number of subjects: 1000
Study 28477794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean delivery
Number of subjects: 0
Study 28477794 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28477848 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 0
Study 28477848 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28478128 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 148
Study 28478128 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA cutoff scores of 20 and 21
Number of subjects: 148
Study 28478128 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA scores <20
Number of subjects: 148
Study 28478128 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IADL measures
Number of subjects: 148
Study 28478485 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (55 kBq/kg body weight every 4 weeks for up to six injections)
Number of subjects: 19
Study 28478485 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (initial single injection of 110 kBq/kg BW followed by up to five injections of 55 kBq/kg BW Q4W)
Number of subjects: 19
Study 28478485 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (overall treatment)
Number of subjects: 19
Study 28478771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-9 mg/d
Number of subjects: 586
Study 28479237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (1 year)
Number of subjects: 0
Study 28479237 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (unspecified duration)
Number of subjects: 0
Study 28479237 — intervention group
Group type: COMPARATOR
Intervention: Traditional immunotherapy (interferon-α and high dose interleukin-2)
Number of subjects: 0
Study 28479237 — intervention group
Group type: COMPARATOR
Intervention: Vascular endothelial growth factor and mTOR inhibitors
Number of subjects: 0
Study 28479237 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (upcoming trials)
Number of subjects: 0
Study 28480049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smokers (female)
Number of subjects: 225
Study 28480049 — intervention group
Group type: EXPERIMENTAL
Intervention: Every one cigarette/day increase in smoking intensity (female)
Number of subjects: 225
Study 28480049 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher smoking intensities (female)
Number of subjects: 225
Study 28480049 — intervention group
Group type: EXPERIMENTAL
Intervention: Past smokers (male)
Number of subjects: 225
Study 28480218 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography Shear Wave Velocity
Number of subjects: 0
Study 28480334 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-valent HPV (4vHPV) vaccine
Number of subjects: 389
Study 28480334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 28480528 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE without aPL (white women)
Number of subjects: 408
Study 28480528 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE without aPL (African American women)
Number of subjects: 408
Study 28480528 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE with aPL (whites)
Number of subjects: 408
Study 28480528 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE with aPL (African Americans)
Number of subjects: 408
Study 28480528 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE with aPL (Hispanics)
Number of subjects: 408
Study 28481606 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorder/housing case management
Number of subjects: 181
Study 28481606 — intervention group
Group type: EXPERIMENTAL
Intervention: VA emergency department services
Number of subjects: 181
Study 28481606 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient services
Number of subjects: 181
Study 28481606 — intervention group
Group type: EXPERIMENTAL
Intervention: VA primary care visits
Number of subjects: 181
Study 28481606 — intervention group
Group type: EXPERIMENTAL
Intervention: VA mental health visits
Number of subjects: 181
Study 28481639 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobian determinant (measure of local lung expansion and contraction with respiration)
Number of subjects: 680
Study 28481639 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of normal voxels within each millimeter distance from emphysematous voxels (mechanically affected lung - MAL)
Number of subjects: 680
Study 28482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet for 8 weeks followed by 6 months of ad libitum diet
Number of subjects: 21
Study 28482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in plasma concentrations of EGFL6, FSTL3, and CRYAB
Number of subjects: 21
Study 28482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline expression of ASPN and USP53
Number of subjects: 21
Study 28482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression quantitative trait loci analysis
Number of subjects: 21
Study 28482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory network involving TGF-β1
Number of subjects: 21
Study 28482070 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated fasting α-hydroxybutyrate levels
Number of subjects: 78
Study 28482070 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma α-hydroxybutyrate and BCAAs during OGTT
Number of subjects: 78
Study 28482070 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline α-hydroxybutyrate concentrations
Number of subjects: 78
Study 28482070 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive α-hydroxybutyrate decrease
Number of subjects: 78
Study 28482144 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg subcutaneously every 6 weeks during period 1 (P1)
Number of subjects: 9
Study 28482144 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab treatment during period 1 (P1)
Number of subjects: 9
Study 28482144 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab treatment during period 2 (P2)
Number of subjects: 9
Study 28482144 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab treatment
Number of subjects: 9